Healio

Skyrizi snags FDA approval for moderate to severe UC; first IL-23 approved for UC, CD

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, ...
Healthline

Skyrizi Interactions: Alcohol, Medications, and Others

Skyrizi is a prescription drug used to treat certain autoimmune conditions, such as Crohn’s disease, in adults. There are currently no known interactions between Skyrizi and other medications, alcohol ...
Seeking Alpha

Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis

NORTH CHICAGO, Ill., March 23, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from INSPIRE, a Phase 3 induction study, showing risankizumab (SKYRIZI ®,1200 mg ...
Seeking Alpha

AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints

* The first primary endpoint was clinical remission (per CDAI) at week 24, and the second primary endpoint was endoscopic remission (per SES-CD) at week 48. Non-inferiority was met for the first ...
Everyday Health

FDA Approves Skyrizi (Risankizumab) for Ulcerative Colitis

In studies, the injected medicine helped a significant number of people with UC find relief from moderate to severe symptoms. The FDA has given its okay to the biologic drug Skyrizi (risankizumab) as ...